Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate
2. Cb 7630
3. Cb-7630
4. Cb7630
5. Zytiga
1. 154229-18-2
2. Zytiga
3. Cb7630
4. Cb-7630
5. Yonsa
6. Cb 7630
7. Abiraterone Acetate [usan]
8. 17-(3-pyridyl)-5,16-androstadien-3beta-acetate
9. Em5ocb9yj6
10. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Acetate
11. Nsc-748121
12. Nsc-749227
13. Chebi:68639
14. (3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl Acetate
15. 17-(pyridin-3-yl)androsta-5,16-dien-3beta-yl Acetate
16. (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl Acetate
17. Abiraterone Acotate
18. 17-(3-pyridyl)androsta-5, Acetate
19. Androsta-5, 17-(3-pyridinyl)-, 3-acetate,
20. Unii-em5ocb9yj6
21. Abiraterone-acetate
22. Ncgc00186462-01
23. 3s,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol, 3-acetate
24. Abiraterone Acetate
25. Mfcd00934213
26. Zytiga (tn)
27. Abiraterone (acetate)
28. Jnj-212082
29. Abiraterone Acetate- Bio-x
30. Dsstox_cid_28969
31. Dsstox_rid_83234
32. Dsstox_gsid_49043
33. Schembl93715
34. Mls006010090
35. Chembl271227
36. Gtpl9288
37. Abiraterone Acetate (jan/usp)
38. 3beta-17-(3-pyridyl)androsta-5,16-dien-3-ol Acetate
39. Abiraterone (as Acetate)
40. Abiraterone Acetate [mi]
41. Dtxsid3049043
42. Abiraterone Acetate [jan]
43. Ex-a107
44. Abiraterone Acetate [vandf]
45. Abiraterone Acetate [mart.]
46. Bcp02949
47. Zinc3809191
48. Tox21_113589
49. Abiraterone Acetate [usp-rs]
50. Abiraterone Acetate [who-dd]
51. Bdbm50407398
52. Nsc748121
53. Nsc749227
54. S2246
55. Abiraterone Acetate, >=98% (hplc)
56. Akos015896502
57. Cs-0544
58. Ds-2007
59. Jnj 212082
60. Nsc 748121
61. Nsc 749227
62. Jnj-2012082
63. Abiraterone Acetate [orange Book]
64. Ncgc00379022-06
65. Ac-25760
66. Ba164133
67. Hy-75054
68. Smr004701235
69. Abiraterone Acetate [usp Monograph]
70. Cas-154229-18-2
71. D09701
72. 3b-acetoxy-17-(3-pyridyl)androsta-5,16-diene
73. A809510
74. 3beta-acetoxy-17-(3-pyridyl)androsta-5,16-diene
75. W-201385
76. Brd-k24048528-001-02-5
77. Q27888393
78. (3s)-3-acetoxy-17-(pyridin-3-yl)androsta-5,16-diene
79. (3?)-17-(3-pyridinyl)androsta-5,16-dien-3-yl Acetate
80. (3beta)-17-(3-pyridinyl)androsta-5,16-dien-3-ol Acetate
81. 17-(pyridin-3-yl)androsta-5,16-dien-3.beta.-yl Acetate
82. Abiraterone Acetate, United States Pharmacopeia (usp) Reference Standard
83. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3beta)-
84. Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, Acetate (ester), (3.beta.)-
85. (1s,2r,5s,10r,11s,15s)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-yl Acetate
86. [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ethanoate
87. Acetic Acid [(3s,8r,9s,10r,13s,14s)-10,13-dimethyl-17-(3-pyridinyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] Ester
| Molecular Weight | 391.5 g/mol |
|---|---|
| Molecular Formula | C26H33NO2 |
| XLogP3 | 5.2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 391.251129295 g/mol |
| Monoisotopic Mass | 391.251129295 g/mol |
| Topological Polar Surface Area | 39.2 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 739 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Zytiga is indicated with prednisone or prednisolone for:
- the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Abiraterone Mylan is indicated with prednisone or prednisolone for:
- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Abiraterone Krka is indicated with prednisone or prednisolone for:
- the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5. 1)
- the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)
- the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Cytochrome P-450 Enzyme Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. (See all compounds classified as Cytochrome P-450 Enzyme Inhibitors.)
Steroid Synthesis Inhibitors
Compounds that bind to and inhibit enzymes involved in the synthesis of STEROIDS. (See all compounds classified as Steroid Synthesis Inhibitors.)
L02BX03
L02BX03
L02BX03
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-13
Pay. Date : 2014-05-05
DMF Number : 28038
Submission : 2014-03-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28292
Submission : 2014-06-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26779
Submission : 2012-12-24
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-03-13
Pay. Date : 2014-12-23
DMF Number : 28383
Submission : 2014-06-13
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-08-09
Pay. Date : 2022-06-16
DMF Number : 27853
Submission : 2013-12-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-05
Pay. Date : 2014-10-14
DMF Number : 28701
Submission : 2014-10-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-12
Pay. Date : 2014-06-27
DMF Number : 27829
Submission : 2013-12-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-14
Pay. Date : 2013-09-06
DMF Number : 27376
Submission : 2013-08-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-11-01
Pay. Date : 2013-01-10
DMF Number : 26725
Submission : 2012-11-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-30
Pay. Date : 2014-04-25
DMF Number : 27989
Submission : 2014-02-12
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 250MG
USFDA APPLICATION NUMBER - 202379
DOSAGE - TABLET;ORAL - 500MG
USFDA APPLICATION NUMBER - 202379
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Granulation
Lubricants & Glidants
Disintegrants & Superdisintegrants
Direct Compression
Co-Processed Excipients
Controlled & Modified Release
Thickeners and Stabilizers
Solubilizers
Film Formers & Plasticizers
Parenteral
Taste Masking
Coloring Agents
Topical
Emulsifying Agents
API Stability Enhancers
Rheology Modifiers
Chewable & Orodispersible Aids
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
90
PharmaCompass offers a list of Abiraterone Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Abiraterone Acetate manufacturer or Abiraterone Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Abiraterone Acetate manufacturer or Abiraterone Acetate supplier.
PharmaCompass also assists you with knowing the Abiraterone Acetate API Price utilized in the formulation of products. Abiraterone Acetate API Price is not always fixed or binding as the Abiraterone Acetate Price is obtained through a variety of data sources. The Abiraterone Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_28969 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_28969, including repackagers and relabelers. The FDA regulates DSSTox_CID_28969 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_28969 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_28969 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_28969 supplier is an individual or a company that provides DSSTox_CID_28969 active pharmaceutical ingredient (API) or DSSTox_CID_28969 finished formulations upon request. The DSSTox_CID_28969 suppliers may include DSSTox_CID_28969 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_28969 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_28969 DMF (Drug Master File) is a document detailing the whole manufacturing process of DSSTox_CID_28969 active pharmaceutical ingredient (API) in detail. Different forms of DSSTox_CID_28969 DMFs exist exist since differing nations have different regulations, such as DSSTox_CID_28969 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DSSTox_CID_28969 DMF submitted to regulatory agencies in the US is known as a USDMF. DSSTox_CID_28969 USDMF includes data on DSSTox_CID_28969's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DSSTox_CID_28969 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DSSTox_CID_28969 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DSSTox_CID_28969 Drug Master File in Japan (DSSTox_CID_28969 JDMF) empowers DSSTox_CID_28969 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DSSTox_CID_28969 JDMF during the approval evaluation for pharmaceutical products. At the time of DSSTox_CID_28969 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DSSTox_CID_28969 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DSSTox_CID_28969 Drug Master File in Korea (DSSTox_CID_28969 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DSSTox_CID_28969. The MFDS reviews the DSSTox_CID_28969 KDMF as part of the drug registration process and uses the information provided in the DSSTox_CID_28969 KDMF to evaluate the safety and efficacy of the drug.
After submitting a DSSTox_CID_28969 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DSSTox_CID_28969 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DSSTox_CID_28969 suppliers with KDMF on PharmaCompass.
A DSSTox_CID_28969 written confirmation (DSSTox_CID_28969 WC) is an official document issued by a regulatory agency to a DSSTox_CID_28969 manufacturer, verifying that the manufacturing facility of a DSSTox_CID_28969 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DSSTox_CID_28969 APIs or DSSTox_CID_28969 finished pharmaceutical products to another nation, regulatory agencies frequently require a DSSTox_CID_28969 WC (written confirmation) as part of the regulatory process.
click here to find a list of DSSTox_CID_28969 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DSSTox_CID_28969 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DSSTox_CID_28969 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DSSTox_CID_28969 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DSSTox_CID_28969 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DSSTox_CID_28969 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DSSTox_CID_28969 suppliers with NDC on PharmaCompass.
DSSTox_CID_28969 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_28969 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_28969 GMP manufacturer or DSSTox_CID_28969 GMP API supplier for your needs.
A DSSTox_CID_28969 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_28969's compliance with DSSTox_CID_28969 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_28969 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_28969 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_28969 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_28969 EP), DSSTox_CID_28969 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_28969 USP).
